Drug intelligence / Profile preview

NMRC-M3V-Ad-PfCA

Development stage
Phase 2
Lead developer
Precigen
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

**NMRC-M3V-Ad-PfCA** is an investigational multivalent, non-replicating human adenovirus serotype 5 vaccine developed by the Naval Medical Research Center for prevention of *Plasmodium falciparum* malaria. The product combines two recombinant Ad5 vectors: one encoding *P. falciparum* circumsporozoite protein and one encoding apical membrane antigen 1. By expressing these parasite antigens in vaccinated individuals, it is intended to elicit humoral and cellular immune responses against pre-erythrocytic and blood-stage malaria parasites. In a Phase 1/2a controlled human malaria infection study, the vaccine was reported to be safe, well tolerated, and immunogenic, but it did not provide protective efficacy against controlled human malaria infection.

Other names
AdPfCANMRC-Multi-antigen Multi-stage Malaria Vaccine-Adenovectored-Plasmodium falciparum CSP and AMA1 antigens
02

Targets

AMA1 (Apical membrane antigen 1)CSP (Circumsporozoite protein)

Beyond the preview

Go deeper on NMRC-M3V-Ad-PfCA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NMRC-M3V-Ad-PfCA.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call